Continue to site >
Trending ETFs

Virtus LifeSci Biotech Clinical Trials ETF

etf
BBC
Dividend policy
Suspended
Price as of:
$ N/A 0
primary theme
Health Care Sector Equity
BBC (ETF)

Virtus LifeSci Biotech Clinical Trials ETF

Dividend policy
Suspended
Price as of:
$ N/A 0
primary theme
Health Care Sector Equity
BBC (ETF)

Virtus LifeSci Biotech Clinical Trials ETF

Dividend policy
Suspended
Price as of:
$ N/A 0
primary theme
Health Care Sector Equity

Name

Price

Aum/Mkt Cap

YIELD & DIV

Exp Ratio

Watchlist

-

-

-

$0.00

0.79%

Vitals

YTD Return

-4.4%

1 yr return

17.8%

3 Yr Avg Return

10.1%

5 Yr Avg Return

19.2%

Net Assets

$40.6 M

Holdings in Top 10

10.1%

52 WEEK LOW AND HIGH

N/A
N/A
N/A

Expenses

OPERATING FEES

Expense Ratio 0.79%

SALES FEES

Front Load N/A

Deferred Load N/A

TRADING FEES

Turnover 81.00%

Redemption Fee N/A


Min Investment

Standard (Taxable)

N/A

IRA

N/A


Fund Classification

Fund Type

Exchange Traded Fund

Investment Style

Health


Name

Price

Aum/Mkt Cap

YIELD & DIV

Exp Ratio

Watchlist

-

-

-

$0.00

0.79%

BBC - Profile

Distributions

  • YTD Total Return -5.8%
  • 3 Yr Annualized Total Return 10.1%
  • 5 Yr Annualized Total Return 19.2%
  • Capital Gain Distribution Frequency N/A
  • Net Income Ratio -0.41%
DIVIDENDS
  • Dividend Yield 0.0%
  • Dividend Distribution Frequency Annually

Fund Details

  • Legal Name
    Virtus LifeSci Biotech Clinical Trials ETF
  • Fund Family Name
    Virtus
  • Inception Date
    Dec 16, 2014
  • Shares Outstanding
    850004
  • Share Class
    N/A
  • Currency
    USD
  • Domiciled Country
    United States
  • Manager
    Matthew Brown

Fund Description

Under normal market conditions, the fund will invest not less than 80% of its assets in component securities of the index. The index seeks to track the performance of the common stock of U.S. exchange-listed biotechnology companies with a primary product offering ("lead drug") that is typically in a Phase 1, Phase 2 or Phase 3 clinical trial stage of development, but prior to receiving marketing approval.


BBC - Performance

Return Ranking - Trailing

Period BBC Return Category Return Low Category Return High Rank in Category (%)
YTD -4.4% -79.9% 39.5% 91.59%
1 Yr 17.8% -28.4% 92.6% 85.35%
3 Yr 10.1%* -0.3% 38.2% 82.43%
5 Yr 19.2%* 2.2% 38.6% 11.97%
10 Yr N/A* 9.4% 21.6% N/A

* Annualized

Return Ranking - Calendar

Period BBC Return Category Return Low Category Return High Rank in Category (%)
2020 30.3% -13.6% 178.2% 13.29%
2019 63.8% 3.8% 63.8% 0.69%
2018 -18.3% -49.7% 21.5% 89.78%
2017 54.4% -59.8% 54.4% 0.74%
2016 -36.6% -36.6% 11.6% 100.00%

Total Return Ranking - Trailing

Period BBC Return Category Return Low Category Return High Rank in Category (%)
YTD -5.8% -80.0% 39.7% 91.55%
1 Yr 17.8% -30.4% 92.6% 76.47%
3 Yr 10.1%* -15.9% 38.2% 80.45%
5 Yr 19.2%* -7.4% 38.6% 9.83%
10 Yr N/A* 9.4% 21.6% N/A

* Annualized

Total Return Ranking - Calendar

Period BBC Return Category Return Low Category Return High Rank in Category (%)
2020 30.3% -13.6% 178.2% 13.37%
2019 63.8% 3.8% 63.8% 0.69%
2018 -18.3% -25.3% 22.2% 91.24%
2017 54.4% -10.8% 54.4% 0.74%
2016 -36.6% -36.6% 11.6% 100.00%

BBC - Holdings

Concentration Analysis

BBC Category Low Category High BBC % Rank
Net Assets 40.6 M 2.72 M 53.2 B 84.09%
Number of Holdings 196 11 478 5.93%
Net Assets in Top 10 4.13 M 2.18 K 21.1 B 76.27%
Weighting of Top 10 10.14% 10.1% 94.7% 100.00%

Top 10 Holdings

  1. Amyris Inc 2.93%
  2. MyoKardia Inc 1.88%
  3. Rubius Therapeutics Inc 1.88%
  4. BioNTech SE ADR 1.71%
  5. Atara Biotherapeutics Inc 1.65%
  6. Denali Therapeutics Inc 1.64%
  7. Moderna Inc 1.64%
  8. NantKwest Inc 1.62%
  9. Kodiak Sciences Inc 1.57%
  10. Mirati Therapeutics Inc 1.54%

Asset Allocation

Weighting Return Low Return High BBC % Rank
Stocks
98.74% 83.68% 104.21% 62.29%
Cash
1.26% -0.65% 9.16% 28.81%
Preferred Stocks
0.00% 0.00% 5.83% 40.25%
Other
0.00% -26.05% 9.11% 47.03%
Convertible Bonds
0.00% 0.00% 0.06% 33.90%
Bonds
0.00% 0.00% 17.12% 36.44%

Stock Sector Breakdown

Weighting Return Low Return High BBC % Rank
Healthcare
99.46% 61.99% 100.00% 56.78%
Basic Materials
0.54% 0.00% 8.23% 21.19%
Utilities
0.00% 0.00% 0.98% 33.90%
Technology
0.00% 0.00% 19.13% 39.41%
Real Estate
0.00% 0.00% 6.19% 36.44%
Industrials
0.00% 0.00% 7.02% 38.14%
Financial Services
0.00% 0.00% 1.92% 52.54%
Energy
0.00% 0.00% 0.71% 33.90%
Communication Services
0.00% 0.00% 7.81% 36.02%
Consumer Defense
0.00% 0.00% 28.21% 39.83%
Consumer Cyclical
0.00% 0.00% 17.63% 37.29%

Stock Geographic Breakdown

Weighting Return Low Return High BBC % Rank
US
86.12% 57.23% 100.70% 56.36%
Non US
12.62% 0.00% 42.77% 44.49%

BBC - Expenses

Operational Fees

BBC Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Expense Ratio 0.79% 0.08% 2.91% 43.97%
Management Fee 0.79% 0.00% 1.25% 69.49%
12b-1 Fee N/A 0.00% 1.00% N/A
Administrative Fee N/A 0.03% 0.25% N/A

Sales Fees

BBC Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Front Load N/A 0.00% 5.75% N/A
Deferred Load N/A 1.00% 5.00% N/A

Trading Fees

BBC Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Max Redemption Fee N/A 1.00% 2.00% N/A

Related Fees

Turnover provides investors a proxy for the trading fees incurred by mutual fund managers who frequently adjust position allocations. Higher turnover means higher trading fees.

BBC Fees (% of AUM) Category Return Low Category Return High Rank in Category (%)
Turnover 81.00% 0.00% 256.00% 77.25%

BBC - Distributions

Dividend Yield Analysis

BBC Category Low Category High BBC % Rank
Dividend Yield 0.00% 0.00% 2.44% 47.88%

Dividend Distribution Analysis

BBC Category Low Category High Category Mod
Dividend Distribution Frequency Annually Annually Monthly Monthly

Net Income Ratio Analysis

BBC Category Low Category High BBC % Rank
Net Income Ratio -0.41% -2.54% 1.92% 76.88%

Capital Gain Distribution Analysis

BBC Category Low Category High Capital Mode
Capital Gain Distribution Frequency

Dividend Payout History

View More +

BBC - Fund Manager Analysis

Managers

Matthew Brown


Start Date

Tenure

Tenure Rank

Aug 14, 2017

4.05

4.1%

Matthew Brown serves as Portfolio Manager at Virtus ETF Advisers LL. Mr. Brown is also executive managing director and chief operating officer at Virtus ETF Solutions LLC (“VES”) since 2012. Before founding VES in 2012, he served as director of operations for Factor Advisors from 2010 to 2012. In 2009, Mr. Brown co-founded ETP Resources, a consulting and data services business that continues to grow and serve the ETF industry. From 2008 to 2009, he headed U.S. operations and served as chief compliance officer for U.K.-based issuer SPA/London & Capital. Mr. Brown earned a B.A. in Economics from Boston College.

Seth Kadushin


Start Date

Tenure

Tenure Rank

Aug 14, 2017

4.05

4.1%

Seth Kadushin serves as Portfolio Manager at Virtus ETF Advisers LLC. Mr. Kadushin has also served as director of capital markets at Virtus ETF Solutions LLC (“VES”) since 2013. Prior to joining VES, Mr. Kadushin worked at Euromoney Institutional Investor, Plc where he developed large scale investment management programs focusing on Exchange Traded Instruments and Alternate Investment Strategies. From 2011 through 2012 Mr. Kadushin worked at Wedbush Securities as an Options Desk Strategist. Mr. Kadushin worked at RBS Securities as Head Program Trader from 2009 through 2011. Prior to 2009, Mr. Kadushin held senior level positions at Lehman Brothers and Bear Sterns (J.P. Morgan), where he was a member of the firm’s Cross Asset Policy Committee charged with instituting their equity trading division’s guidelines. Mr. Kadushin holds a BBA in Finance from Emory University. He achieved his Master’s in Business from Fordham University with a concentration in Information Systems.

Tenure Analysis

Category Low Category High Category Average Category Mode
0.03 23.98 6.66 1.38